Home › Funds › Paradigm Biocapital Advisors LP › EYPT
Paradigm Biocapital Advisors LP position in EYPT
EYEPOINT INC · Industrials
Paradigm Biocapital Advisors LP reported holding 2,890,397 shares of EYPT (EYEPOINT INC) in its Q2 2026 13F filing — a position valued at US$41.3M, representing 0.77% of its reported portfolio and ranking #21 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed EYPT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's EYPT position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in EYPT in Q3 2025 at 2,005,365 shares (US$28.6M). The position peaked in Q4 2025 at 3,691,475 shares, worth US$67.4M. Across 4 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,890,397 shares valued at US$41.3M — a reduction of -252,040 shares quarter over quarter.. Notable position changes include a 84% increase in Q4 2025 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.01M | $28.56M | New |
| Q4 2025 | 3.69M | $67.44M | Add |
| Q1 2026 | 3.14M | $40.51M | Reduce |
| Q2 2026 | 2.89M | $41.33M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EYPT and 13F data
EYPT (EYEPOINT INC) is a Industrials company. 42 other funds we track also report a position in EYPT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$118.6M), Cormorant Asset Management, LP (US$100.1M), Commodore Capital LP (US$65.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EYPT
- MONTANOVA CAPITAL, LLC 8.30M sh · $118.64M · Q2 2026
- Cormorant Asset Management, LP 7.00M sh · $100.10M · Q2 2026
- Commodore Capital LP 4.60M sh · $65.78M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.00M sh · $28.60M · Q2 2026
- Parkman Healthcare Partners LLC 1.29M sh · $18.42M · Q2 2026
- Essex Woodlands Management, Inc. 1.08M sh · $15.51M · Q2 2026
- 5AM Venture Management, LLC 1.05M sh · $15.02M · Q2 2026
- Rosalind Advisors, Inc. 988.23K sh · $14.13M · Q2 2026
- Artia Global Partners LP 767.10K sh · $10.97M · Q2 2026
- Blue Owl Capital Holdings LP 762.59K sh · $10.91M · Q2 2026
- Patient Square Capital LP 720.00K sh · $10.30M · Q2 2026
- Principia Wealth Advisory, LLC 649.94K sh · $9.29M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held EYPT?
Paradigm Biocapital Advisors LP has disclosed EYPT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Paradigm Biocapital Advisors LP's current position in EYPT?
As of Q2 2026, Paradigm Biocapital Advisors LP holds 2.89M shares of EYPT (EYEPOINT INC), valued at $41.33M, representing 0.77% of its reported portfolio and ranking #21.
Has Paradigm Biocapital Advisors LP been buying or selling EYPT?
In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP reduced its position in EYPT. The position peaked in Q4 2025 at 3.69M shares.
Which other funds hold EYPT?
Other major institutional holders of EYPT include MONTANOVA CAPITAL, LLC, Cormorant Asset Management, LP, Commodore Capital LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.